Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data | Scientific Reports
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
New Protocol for Advanced Kidney Cancer Involving Drug Combo of Avelumab and Axitinib - Thailand Medical News
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study -
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial | Journal for ImmunoTherapy of Cancer
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma | NEJM
Avelumab timeline from discovery to Merck-Pfizer Alliance, breakthrough... | Download Scientific Diagram
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial - Journal of Thoracic Oncology
Multicenter Clinical Trial is Currently Recruiting MCC Patients - Merkel Cell Carcinoma
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - Annals of Oncology
![PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/63896bbe64c237acb7d4260c2e84ab3aa4969933/35-Figure1-1.png "PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar")
PDF] Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy | Semantic Scholar
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer - Cancer Treatment Reviews
Cancers | Free Full-Text | The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials | HTML
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy - Annals of Oncology
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial - The Lancet Oncology
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ESMO Open
Select clinical trials evaluating avelumab in combination with other... | Download Table
